Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
NCT01611480 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2013-06-26
Summary
The aim is to evaluate efficacy and safety of three different dosing regimens of Limtop in a study involving 96 patients with actinic keratosis on the head or face.
Conditions
- Actinic Keratosis
Interventions
- DRUG
-
Imiquimod (topical use)
Sponsors & Collaborators
-
Moberg Pharma AB
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Primary Completion
- 2013-01-31
Countries
- Germany
More Related Trials
-
1-Year Follow up to the 1473-IMIQ Study
NCT00114023 ·Status: COMPLETED
-
Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year
NCT00668733 ·Status: COMPLETED
-
Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
NCT00189306 ·Status: COMPLETED ·Phase: PHASE3
-
Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers
NCT03071679 ·Status: COMPLETED ·Phase: PHASE1
-
Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
NCT00066872 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
NCT00189241 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts
NCT04290572 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts:Randomized Comparative Trial.
NCT06973473 ·Status: NOT_YET_RECRUITING
-
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
NCT00129519 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
NCT03278028 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03812510 ·Status: COMPLETED ·Phase: PHASE3
-
Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03687372 ·Status: COMPLETED ·Phase: PHASE3
-
Topical Imiquimod Treatment of Oral Dysplasia
NCT07210775 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
NCT00314756 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03691831 ·Status: COMPLETED ·Phase: PHASE3
-
Study With a Topical Gel to Treat Common Warts in Adults
NCT00117871 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Immune Responses to Topical Imiquimod
NCT04809662 ·Status: TERMINATED
-
A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts
NCT05146895 ·Status: UNKNOWN ·Phase: NA
-
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
NCT03210337 ·Status: COMPLETED ·Phase: PHASE2
-
Study With a Topical Gel to Treat Common Warts in Adults
NCT00117923 ·Status: COMPLETED ·Phase: PHASE2
-
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
NCT00114920 ·Status: COMPLETED ·Phase: PHASE2
-
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
NCT00116675 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
NCT01808950 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal
NCT00638651 ·Status: COMPLETED ·Phase: PHASE1
-
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453
NCT02052687 ·Status: COMPLETED ·Phase: PHASE1